Clinical Trials Logo

Clinical Trial Summary

This phase II trial tests how well pertuzumab, trastuzumab, hyaluronidase-zzxf and enzalutamide works in treating patients with castration-resistant prostate cancer that has spread from where it first started to other places in the body (metastatic). Pertuzumab and trastuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called human epidermal growth factor receptor-2 (HER2). HER2 is found on some cancer cells. When pertuzumab or trastuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows pertuzumab and trastuzumab to be given by injection under the skin and shortens their administration time compared to pertuzumab or trastuzumab alone. Chemotherapy drugs, such as enzalutamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pertuzumab, trastuzumab, hyaluronidase-zzxf and enzalutamide may kill more cancer cells.


Clinical Trial Description

PRIMARY OBJECTIVE: I. Evaluate the combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf plus enzalutamide in enzalutamide-refractory metastatic castration-resistant prostate cancer (mCRPC) in improving objective response rate among patients with measurable disease (Prostate Cancer Clinical Trials Working Group 3 [PCWG 3.0]). SECONDARY OBJECTIVES: I. Evaluate this combination for radiographic progression-free survival at 6 months. II. Evaluate this combination for overall survival at 12 months. EXPLORATORY OBJECTIVES: I. Assessment of this combination for adverse events according to clinical judgment and patient-reported outcomes (Patient Reported Outcomes-Common Terminology Criteria for Adverse Events [PRO-CTCAE] - Prostate Cancer). II. Assessment of patient quality of life using Functional Assessment of Cancer Therapy- Prostate (FACT-P) questionnaire. CORRELATIVE OBJECTIVES: I. Determine the correlation between outcomes as above and systemic NRG-1 levels at baseline and over time. II. Determine the correlation between outcomes as above and change in HER2/HER3/androgen receptor (AR) gene signatures. OUTLINE: Patients receive pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneously (SC) and enzalutamide orally (PO) on study. Patients undergo echocardiography (ECHO), biopsy, computed tomography (CT), and magnetic resonance imaging (MRI) scans. Patients also undergo collection of blood and tissue samples. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05730712
Study type Interventional
Source Mayo Clinic
Contact
Status Recruiting
Phase Phase 2
Start date March 8, 2024
Completion date October 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04716725 - 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer Phase 2
Active, not recruiting NCT03218826 - PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Active, not recruiting NCT04033432 - sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT01881867 - CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Not yet recruiting NCT06236139 - Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Recruiting NCT04071236 - Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Phase 1/Phase 2
Active, not recruiting NCT02522715 - Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Phase 1/Phase 2
Terminated NCT04951492 - Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Active, not recruiting NCT03344211 - Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT02312557 - Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide Phase 2
Recruiting NCT04159896 - ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase 2
Completed NCT05547386 - 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer Phase 3
Recruiting NCT05960578 - Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study Phase 2
Recruiting NCT06200103 - Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Phase 2
Active, not recruiting NCT03517969 - M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT06039371 - Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Phase 2
Active, not recruiting NCT02703623 - Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT04777071 - An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer Phase 2
Active, not recruiting NCT03805594 - 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1